Skip to Main Content

Susan M. Chang



Dr. Susan Chang is a neuro-oncologist who specializes in treating adults with brain tumors. She is director of neuro-oncology at the Brain Tumor Center.

Chang also performs studies of experimental brain tumor treatments and evaluates the use of imaging techniques as treatment tools. Specifically, she was one of the recipients of a SPORE grant for evaluating the role of magnetic resonance spectroscopy in diagnosing tumors and evaluating therapeutic interventions. SPORE, which stands for Specialized Programs of Research Excellence, is a program of the National Cancer Institute. She is a principal investigator of a research project funded by the National Institutes of Health that focuses on optimizing the management of patients with glioblastoma, an aggressive brain cancer that's difficult to treat.

In addition, Chang is medical director of the UCSF Neuro-Oncology Gordon Murray Caregiver Program, developed to address the needs of family members and others who care for patients with brain tumors.

Chang received her medical degree from the University of British Columbia and completed a residency in internal medicine at Plains Health Centre and Toronto General Hospital. She completed a fellowship in medical oncology at Princess Margaret Hospital in Toronto as well as a fellowship in neuro-oncology at UCSF, where she later joined the faculty.

  • Education

    University of British Columbia School of Medicine, 1985

  • Residencies

    Plains Health Centre/Toronto General Hospital, Internal Medicine, 1990

  • Fellowships

    University of Toronto Medical Center, Medical Oncology, 1991

    UCSF Medical Center, Neuro-Oncology, 1995

  • Academic Title


Where I see patients (1)

    My work

    Unique program supports loved ones caring for patients with brain cancer

    Dr. Chang helped establish our Neuro-Oncology Gordon Murray Caregiver Program, which supports loved ones caring for patients with brain tumors.

    Decorative Caduceus

    Hyperpolarized Carbon-13 Alpha-ketoglutarate Imaging in IDH Mutant Glioma

    Signal-to-noise ratio (SNR) of HP 13C-aKG will be calculated voxel-by-voxel, and within each region of interest (ROI). The parameters considered will be the mean SNR, within these ROIs. Acquisition parameters will be optimized (su...


    Decorative Caduceus

    Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma

    Safety evaluation for endpoint will include monitoring for the occurrence of treatment-emergent adverse events (AEs). Reported toxicities will be graded using the National Cancer Institute (NCI) Common Terminology (Toxicity) Crite...


    Decorative Caduceus

    Hyperpolarized Imaging in Diagnosing Participants With Glioma

    Adverse events will be monitored from just before investigational medicinal product (IMP) administration until the end of study participation. Vital signs (blood pressure and heart rate only) will be recorded at baseline and 30 mi...